Cart
sales@molnova.com
AXL-IN-13
CAS No. 2376928-82-2
AXL-IN-13( —— )
Catalog No. M36512 CAS No. 2376928-82-2
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 120 | Get Quote |
|
| 5MG | 181 | Get Quote |
|
| 10MG | 266 | Get Quote |
|
| 25MG | 442 | Get Quote |
|
| 50MG | 632 | Get Quote |
|
| 100MG | 898 | Get Quote |
|
| 500MG | 1791 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAXL-IN-13
-
NoteResearch use only, not for human use.
-
Brief DescriptionAXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.
-
DescriptionAXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
-
In VitroWestern Blot Analysis Cell Line:MDA-MB-231 cells Concentration:0, 0.11, 0.33, 1, 3 μM.Incubation Time:3 daysResult:Restored the protein levels of E-cadherin and N-cadherin to control levels.Cell Migration Assay Cell Line:MDA-MB-231 cell Concentration:0, 0.11, 0.33, 1, 3 μM.Incubation Time:24 h Result:Inhibited cell migration at 1 and 3 μM.Inhibited the invasion of MDA-MB-231 cells by 22.6, 34.8, 56.5, and 70.4% at the concentrations of 0.11, 0.33, 1.0, and 3.0 μM, respectively.
-
In VivoAnimal Model:Xenograft model derived from highly metastatic 4T1 cells.Dosage:50 or 100 mg/kg Administration:Oral administration (p.o.)Result:Suppressed 4T1 tumor growth with a tumor growth inhibition (TGI) of 78.0 and 95.9% at 50 and 100 mg/kg, respectively. Inhibited the phosphorylation of AXL. Showed that liver is one of the most common sites of breast cancer metastasis.Animal Model:Rats Dosage:5 mg/kg (i.v.), 25 mg/kg (p.o.) Administration:Intravenous injection (i.v.), oral administration (p.o.)Result:Pharmacokinetic parameters of AXL-IN-13 (Compound 6li).
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT | PDGFR | TGF-beta/Smad | TAM Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2376928-82-2
-
Formula Weight632.72
-
Molecular FormulaC34H41FN6O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (158.05 mM; Ultrasonic )
-
SMILESO(C=1C2=C(C=C(OCCCN3CCOCC3)C(OC)=C2)N=CC1)C4=C(F)C=C(NC=5C(C(NC6CCCCC6)=O)=CN(C)N5)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chan S, et al. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. J Med Chem. 2022 Nov 24;65(22):15374-15390. ?
molnova catalog
related products
-
Gilteritinib hemifum...
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
-
Pacritinib
Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.
-
BGB-102
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
